Sichenzia Ross Friedman Ference LLP Advises Underwriter Aegis Capital on U.S. Initial Public Offering of Israeli Biopharmaceutical Company
Represents first Israeli-American collaborative transaction between affiliated law firms SRFF LLP and DTKGC & Co.
New York, NY – May 15, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP (“SRFF”) announced today that the Firm has represented the underwriter Aegis Capital Corp. on the U.S. initial public offering of BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an Israeli biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infection diseases. The public offering involved the sale of 1,910,000 American Depositary Shares (ADSs), with each ADS representing 40 of its ordinary shares, and warrants to purchase 1,910,000 ADSs (excluding over-allotment option) at an offering price of $5.00 per ADS and $0.01 per warrant. Biondvax raised approximately $9,550,000 in gross proceeds.
This is the first collaborative transaction completed between SRFF and its new affiliate Israeli law firm, Doron, Tikotzky, Kantor, Gutman, Cederboum & Co. (“DTKGC”). DTKGC’s partner Ronen Kantor led the Israeli team and represented Aegis Capital Corp. as the underwriter in Israel and SRFF’s partner Gregory Sichenzia and Associate Gary Emmanuel advised Aegis Capital Corp. as underwriter in the U.S. SRFF and DTKGC launched an affiliate partnership earlier this month to provide their Israeli and American clients the ability to seamlessly conduct public offerings in the U.S. and Israeli capital markets.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Attorneys Selected for Inclusion on 2019 Super Lawyers Lists - October 16, 2019
- Sichenzia Ross Ference LLP to Join Client Relmada Therapeutics, Inc. at Nasdaq Opening Bell Ringing - October 15, 2019
- Sichenzia Ross Ference LLP Congratulates Relmada Therapeutics, Inc., on NASDAQ Uplisting - October 10, 2019